AbbVie ROE 2010-2022 | ABBV

Current and historical return on equity (ROE) values for AbbVie (ABBV) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
AbbVie ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $12.64B $14.69B 84.23%
2022-03-31 $12.48B $16.31B 86.18%
2021-12-31 $11.54B $15.44B 83.43%
2021-09-30 $7.53B $13.58B 56.86%
2021-06-30 $6.66B $12.59B 48.71%
2021-03-31 $5.16B $13.73B 36.30%
2020-12-31 $4.62B $13.10B 51.72%
2020-09-30 $7.38B $15.29B 204.54%
2020-06-30 $6.96B $14.73B -306.44%
2020-03-31 $8.44B $-7.42B -104.22%
2019-12-31 $7.88B $-8.17B -96.15%
2019-09-30 $3.26B $-8.23B -39.38%
2019-06-30 $4.12B $-8.57B -59.34%
2019-03-31 $5.36B $-7.83B -95.00%
2018-12-31 $5.69B $-8.45B -203.31%
2018-09-30 $7.57B $-2.92B 1285.47%
2018-06-30 $6.45B $-3.38B 215.65%
2018-03-31 $6.38B $3.55B 119.57%
2017-12-31 $5.31B $5.10B 93.18%
2017-09-30 $6.65B $6.69B 119.09%
2017-06-30 $6.62B $6.01B 119.66%
2017-03-31 $6.31B $5.00B 116.08%
2016-12-31 $5.95B $4.64B 111.33%
2016-09-30 $6.08B $6.47B 117.49%
2016-06-30 $5.72B $5.64B 119.85%
2016-03-31 $5.48B $4.64B 115.56%
2015-12-31 $5.14B $3.95B 131.15%
2015-09-30 $2.82B $4.86B 83.55%
2015-06-30 $2.08B $5.50B 62.83%
2015-03-31 $1.82B $1.38B 55.95%
2014-12-31 $1.77B $1.74B 43.53%
2014-09-30 $3.71B $4.65B 77.93%
2014-06-30 $4.17B $5.22B 92.75%
2014-03-31 $4.14B $4.70B 101.45%
2013-12-31 $4.13B $4.49B 113.22%
2013-09-30 $4.54B $3.58B 134.97%
2013-06-30 $5.16B $3.56B 80.81%
2013-03-31 $5.36B $2.96B 64.01%
2012-12-31 $5.28B $3.36B 49.54%
2012-09-30 $4.89B $15.67B 38.25%
2012-06-30 $3.32B $11.51B 37.42%
2012-03-31 $3.59B $12.05B 59.93%
2011-12-31 $3.43B $11.93B 115.09%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $249.673B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17